GMTX - Gemini Therapeutics completes enrollment in mid-stage wet AMD trial

Gemini Therapeutics (GMTX) announces the completion of enrollment in its Phase 2a trial testing GEM103 as a potential add-on therapy for certain patients suffering from wet Age-related macular degeneration ((AMD)), a progressive retinal disease.The trial looks at treating wet AMD patients requiring continued anti-vascular endothelial growth factor ((anti-VEGF)) treatment who may be at risk for macular atrophy ((MA)).It is designed to enroll about 45 patients randomized 2:1 between GEM103 plus aflibercept and sham plus aflibercept arms, with treatment administered via intravitreal injection every other month for twelve months.Topline data related to safety, tolerability, effect on intraocular complement factor H ((CFH)) levels and disease-relevant biomarkers of complement regulation is expected in late 2021, the company said.Shares down 1% premarket.

For further details see:

Gemini Therapeutics completes enrollment in mid-stage wet AMD trial